FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitors in a Murine Model of Chronic Myelomonocytic Leukemia

Cancer Cell

Volumn 12, Issue 4, 2007, Pages 367-380

  Lee, Benjamin H ^a,b   Tothova, Zuzana ^a   Levine, Ross L ^a,b   Anderson, Kristina ^c   Buza Vidas, Natalija ^c   Cullen, Dana E ^a   McDowell, Elizabeth P ^a   Adelsperger, Jennifer ^a   Fröhling, Stefan ^a   Huntly, Brian J P ^d   Beran, Miloslav ^e   Jacobsen, Sten Eirik ^c   Gilliland, D Gary ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CELLCYCLE; STEMCELL

Indexed keywords

CD135 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL COUNT; CELL CYCLE; CELL FATE; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE LOCUS; MOUSE; MULTIPOTENT STEM CELL; MUTATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALIA; MURINAE;

EID: 35048848955     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.08.031     Document Type: Article

References (60)

1. Akashi K., Traver D., Miyamoto T., and Weissman I.L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404 (2000) 193-197
2. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347 (2002) 481-487
3. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 (2003) 173-183
4. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R., and Korsmeyer S.J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30 (2002) 41-47
5. Baldwin B.R., Li L., Tse K.F., Small S., Collector M., Whartenby K.A., Sharkis S.J., Racke F., Huso D., and Small D. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. Leukemia 21 (2007) 764-771
6. Beran M., Wen S., Shen Y., Onida F., Jelinek J., Cortes J., Giles F., and Kantarjian H. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System. Leuk. Lymphoma 48 (2007) 1150-1160
7. Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., Buerger H., Muller-Tidow C., Choudhary C., McMahon M., et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 65 (2005) 9643-9650
8. Carow C.E., Levenstein M., Kaufmann S.H., Chen J., Amin S., Rockwell P., Witte L., Borowitz M.J., Civin C.I., and Small D. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87 (1996) 1089-1096
9. Cheng T., Rodrigues N., Shen H., Yang Y., Dombkowski D., Sykes M., and Scadden D.T. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287 (2000) 1804-1808
10. Choudhary C., Schwable J., Brandts C., Tickenbrock L., Sargin B., Kindler T., Fischer T., Berdel W.E., Muller-Tidow C., and Serve H. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 106 (2005) 265-273
11. DaSilva N., Hu Z.B., Ma W., Rosnet O., Birnbaum D., and Drexler H.G. Expression of the FLT3 gene in human leukemia-lymphoma cell lines. Leukemia 8 (1994) 885-888
12. David M., Cross N.C., Burgstaller S., Chase A., Curtis C., Dang R., Gardembas M., Goldman J.M., Grand F., Hughes G., et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109 (2007) 61-64
13. Deguchi K., Ayton P.M., Carapeti M., Kutok J.L., Snyder C.S., Williams I.R., Cross N.C., Glass C.K., Cleary M.L., and Gilliland D.G. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 3 (2003) 259-271
14. Drexler H.G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 10 (1996) 588-599
15. Fenaux P., Beuscart R., Lai J.L., Jouet J.P., and Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: An analysis of 107 cases. J. Clin. Oncol. 6 (1988) 1417-1424
16. Frohling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., Dohner H., and Dohner K. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100 (2002) 4372-4380
17. Gabbianelli M., Pelosi E., Montesoro E., Valtieri M., Luchetti L., Samoggia P., Vitelli L., Barberi T., Testa U., Lyman S., et al. Multi-level effects of flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 86 (1995) 1661-1670
18. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
19. Grundler R., Miething C., Thiede C., Peschel C., and Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 105 (2005) 4792-4799
20. Hayakawa F., Towatari M., Kiyoi H., Tanimoto M., Kitamura T., Saito H., and Naoe T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19 (2000) 624-631
21. Hjertson M., Sundstrom C., Lyman S.D., Nilsson K., and Nilsson G. Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells. Exp. Hematol. 24 (1996) 748-754
22. Horiike S., Yokota S., Nakao M., Iwai T., Sasai Y., Kaneko H., Taniwaki M., Kashima K., Fujii H., Abe T., and Misawa S. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 11 (1997) 1442-1446
23. Ishii E., Zaitsu M., Ihara K., Hara T., and Miyazaki S. High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells. Pediatr. Hematol. Oncol. 16 (1999) 437-441
24. Kelly L.M., Kutok J.L., Williams I.R., Boulton C.L., Amaral S.M., Curley D.P., Ley T.J., and Gilliland D.G. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl. Acad. Sci. USA 99 (2002) 8283-8288
25. Kelly L.M., Liu Q., Kutok J.L., Williams I.R., Boulton C.L., and Gilliland D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99 (2002) 310-318
26. Kiyoi H., Naoe T., Nakano Y., Yokota S., Minami S., Miyawaki S., Asou N., Kuriyama K., Jinnai I., Shimazaki C., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93 (1999) 3074-3080
27. Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H., and Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12 (1998) 1333-1337
28. Kondo M., Weissman I.L., and Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91 (1997) 661-672
29. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., Walker H., Wheatley K., Bowen D.T., Burnett A.K., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
30. Lee B.H., Williams I.R., Anastasiadou E., Boulton C.L., Joseph S.W., Amaral S.M., Curley D.P., Duclos N., Huntly B.J., Fabbro D., et al. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 24 (2005) 7882-7892
31. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
32. Li L., Piloto O., Kim K.T., Ye Z., Nguyen H.B., Yu X., Levis M., Cheng L., and Small D. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br. J. Haematol. 137 (2007) 64-75
33. Lin P., Jones D., Medeiros L.J., Chen W., Vega-Vazquez F., and Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am. J. Clin. Pathol. 126 (2006) 530-533
34. Mackarehtschian K., Hardin J.D., Moore K.A., Boast S., Goff S.P., and Lemischka I.R. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3 (1995) 147-161
35. Meierhoff G., Dehmel U., Gruss H.J., Rosnet O., Birnbaum D., Quentmeier H., Dirks W., and Drexler H.G. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 9 (1995) 1368-1372
36. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C., Gruning W., Kratz-Albers K., Serve S., Steur C., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96 (2000) 3907-3914
37. Morrison S.J., and Weissman I.L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1 (1994) 661-673
38. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., and Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10 (1996) 1911-1918
39. Onida F., Kantarjian H.M., Smith T.L., Ball G., Keating M.J., Estey E.H., Glassman A.B., Albitar M., Kwari M.I., and Beran M. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood 99 (2002) 840-849
40. Paietta E., Ferrando A.A., Neuberg D., Bennett J.M., Racevskis J., Lazarus H., Dewald G., Rowe J.M., Wiernik P.H., Tallman M.S., and Look A.T. Activating FLT3 mutations in CD117/KIT positive T-Cell acute lymphoblastic leukemias. Blood 104 (2004) 558-560
41. Pardanani A., Reeder T.L., Kimlinger T.K., Baek J.Y., Li C.Y., Butterfield J.H., and Tefferi A. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk. Res. 27 (2003) 739-742
42. Rasko J.E., Metcalf D., Rossner M.T., Begley C.G., and Nicola N.A. The flt3/flk-2 ligand: Receptor distribution and action on murine haemopoietic cell survival and proliferation. Leukemia 9 (1995) 2058-2066
43. Ratajczak M.Z., Ratajczak J., Ford J., Kregenow R., Marlicz W., and Gewirtz A.M. FLT3/FLK-2 (STK-1) Ligand does not stimulate human megakaryopoiesis in vitro. Stem Cells 14 (1996) 146-150
44. Reindl C., Bagrintseva K., Vempati S., Schnittger S., Ellwart J.W., Wenig K., Hopfner K.P., Hiddemann W., and Spiekermann K. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 107 (2006) 3700-3707
45. Ren R. Modeling the dosage effect of oncogenes in leukemogenesis. Curr. Opin. Hematol. 11 (2004) 25-34
46. Rocnik J.L., Okabe R., Yu J.C., Lee B.H., Giese N., Schenkein D.P., and Gilliland D.G. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 108 (2006) 1339-1345
47. Rosnet O., and Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit. Rev. Oncog. 4 (1993) 595-613
48. Rosnet O., Buhring H.J., Marchetto S., Rappold I., Lavagna C., Sainty D., Arnoulet C., Chabannon C., Kanz L., Hannum C., and Birnbaum D. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10 (1996) 238-248
49. Scheijen B., Ngo H.T., Kang H., and Griffin J.D. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 23 (2004) 3338-3349
50. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., Loffler H., Sauerland C.M., Serve H., Buchner T., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100 (2002) 59-66
51. Smith B.D., Levis M., Beran M., Giles F., Kantarjian H., Berg K., Murphy K.M., Dauses T., Allebach J., and Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
52. Stirewalt D.L., Meshinchi S., Kussick S.J., Sheets K.M., Pogosova-Agadjanyan E., Willman C.L., and Radich J.P. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br. J. Haematol. 124 (2004) 481-484
53. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3 (2003) 650-665
54. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., Grandin W., Lebwohl D., Wang Y., Cohen P., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
55. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., Wermke M., Bornhauser M., Ritter M., Neubauer A., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
56. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., McDowell E.P., Lazo-Kallanian S., Williams I.R., Sears C., et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128 (2007) 325-339
57. Wadleigh M., DeAngelo D.J., Griffin J.D., and Stone R.M. After chronic myelogenous leukemia: Tyrosine kinase inhibitors in other hematologic malignancies. Blood 105 (2005) 22-30
58. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
59. Whitman S.P., Archer K.J., Feng L., Baldus C., Becknell B., Carlson B.D., Carroll A.J., Mrozek K., Vardiman J.W., George S.L., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res. 61 (2001) 7233-7239
60. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., Asou N., Kuriyama K., Yagasaki F., Shimazaki C., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 (2001) 2434-2439